title: [Economic aspects of hospitaly treated pneumococcal pneumonia and the results of Pneumo 23 vaccine use in Serbia].
abstract: BACKGROUND
  In Serbia, there is a significant number of persons suffering of pneumococcal pneumonia. Persons aged 65 years or older, immunocompromised patients, patients with co-morbidities, such as chronic obstructive lung disease and congestive heart failure, are at the highest risk for developing pneumococcal pneumonia. Most of the patients are treated empirically, although it is often overlooked that Streptococcus pneumoniae can be resistant to the used antibiotics. The treatment costs of such inpatients and outpatients are very high. In Serbia, immunization of persons at risk to develop the diseases caused by Streptococcus pneumoniae is carried out using pneumococcus polysaccharide vaccine according to clinical indications. The exact number of immunized persons and the total number of registered patients are still unknown, but it is certain of being unjustifiably low.
  
  
  OBJECTIVE
  The goal of the study was to investigate, during a one-year period, the number and basic characteristics of persons hospitably treated for pneumonia, the type of cause of the infection, applied antibiotic medications, duration and costs of hospital treatment at the Institute for Lung Diseases and Tuberculosis of the Clinical Centre of Serbia in Belgrade.
  
  
  METHODS
  We retrospectively analyzed the medical records of patients with pneumonia treated at the Institute for Lung Diseases and Tuberculosis of the Clinical Centre of Serbia in Belgrade during 2006.
  
  
  RESULTS
  During the observed one-year period, 290 patients underwent hospital treatment, of whom the cause of the infection was confirmed in 116 (40%). The average duration of hospitalization was 12 days, with treatment cost of 32,031.74 RSD (402.42 EUR) per patient. The treatment cost per patient including general and intensive care was 18,290.01 RSD (229.78 EUR). The distribution cost of Pneumo 23 vaccine in Serbia, without purchase tax, was 746.90 RSD (9.38 EUR).
  
  
  CONCLUSIONS
  Pneumococcal pneumonia is a significant medical and economic problem for the healthcare system of Serbia. The use of antipneumococcal vaccination can be useful in decreasing the overall treatment costs related to pneumococcal infection.
authors.forename: Tatjana
authors.initials: T
authors.lastname: Adzić
authors.forename: Ilija
authors.initials: I
authors.lastname: Rosić
authors.forename: Dragana
authors.initials: D
authors.lastname: Jovanović
authors.forename: Snezana
authors.initials: S
authors.lastname: Medić-Stojanac
mesh_terms: D017048:Health Care Costs; D006760:Hospitalization / Q000191:economics*; D006801:Humans; D022242:Pneumococcal Vaccines / Q000191:economics*; D011018:Pneumonia, Pneumococcal / Q000191:economics* / Q000517:prevention & control* / Q000628:therapy; D011135:Polysaccharides, Bacterial / Q000191:economics; D055771:Serbia
chemical_list: C414006:23-valent pneumococcal capsular polysaccharide vaccine; D022242:Pneumococcal Vaccines; D011135:Polysaccharides, Bacterial